Candidate anti-herpesviral drugs; mechanisms of action and resistance

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis

Volumn , Issue , 2007, Pages 1219-1250

  Biron, Karen K ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929284077     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545313.069     Document Type: Chapter

References (185)

1. Abele, G., Cox, S., Bergman, S. et al. (1991). Antiviral activity against VZV and HSV type 1 and type 2 of the (+) and (?) enan-tiomers of (R, S)-9-[4-hydroxy-2-(hydroxymethyl) butyl] gua-nine, in comparison to other closely related acyclic nucleo-sides. Antivir. Chem. Chemother., 2, 163-169.
2. Abenes, G., Lee, M., Haghjoo, E., Tong, T., Zhan, X., and Liu, F. (2001). Murine cytomegalovirus open reading frame M27 plays an important role in growth and virulence in mice. J. Virol., 75, 1697-1707.
3. Ablashi, D. V., Chatlynne, L. G., Whitman, J. E., Jr., and Cesarman, E. (2002). Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin. Microbiol. Rev., 15, 439-464.
4. Akanitapichat, P. and Bastow, K. F. (2002). The antiviral agent 5-chloro-1,3-dihydroxyacridone interferes with assembly and maturation of herpes simplex virus. Antiviral Res., 53, 113-126.
5. Akanitapichat, P., Lowden, C. T., and Bastow, K. F. (2000).1,3-dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res., 45, 123-134.
6. Aldern, K. A., Ciesla, S. L., Winegarden, K. L., and Hostetler, K. Y. (2003). Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol., 63, 678-681.
7. Arkin, M. R. and Wells, J. A. (2004). Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat. Rev. Drug Discov., 3, 301-317.
8. Azzeh, M., Honigman, A., Taraboulos, A., Rouvinski, A., and Wolf, D. G. (2006). Structural changes in human cytomegalovirus cyto-plasmic assembly sites in the absence of UL97 kinase activity. Virology, in press.
9. Baba, M., Nishimura, O., Kanzaki, N. et al. (1999). A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl Acad Sci. USA, 96, 5698-5703.
10. Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T., and Sutton, D. (2003). Herpes simplex virus resistance to acyclovir and pen-ciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev., 16, 114-128.
11. Baek, M. C., Krosky, P. M., He, Z., and Coen, D. M. (2002). Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Impor-tance of the P+5 position. J. Biol. Chem., 277, 29593-29599.
12. Balzarini, J. and McGuigan, C. (2002). Bicyclic pyrimidine nucle-oside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication. J. Antimicrob. Chemother., 50, 5-9.
13. Balzarini, J., Sienaert, R., Liekens, S. et al. (2002). Lack of suscepti-bility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol. Pharmacol., 61, 1140-1145.
14. Beadle, J. R., Wan, W.B., Ciesla, S. L. et al. (2006). Synthe-sis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirusandorthopoxviruses. J. Med.Chem., 49, 2010-2015.
15. Beard, P. M., Taus, N. S., and Baines, J. D. (2002). DNA cleavage and packaging proteins encoded by genes U(L)28, U(L)15, and U(L)33 of herpes simplex virus type 1 form a complex in infected cells. J. Virol., 76, 4785-4791.
16. Bernstein, D. I., Harrison, C. J., Tomai, M. A., and Miller, R. L. (2001). Daily or weekly therapy with resiquimod (R-848) reduces gen-ital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J. Infect. Dis., 183, 844-849.
17. Betz, U. A., Fischer, R., Kleymann, G., Hendrix, M., and Rubsamen-Waigmann, H. (2002). Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother., 46, 1766-1772.
18. Bidanset, D. J., Beadle, J. R., Wan, W. B., Hostetler, K. Y., and Kern, E. R. (2004). Oral activity of ether lipid ester prodrugs of cido-fovir against experimental human cytomegalovirus infection. J. Infect. Dis., 190, 499-503.
19. Biron, K. K., Harvey, R. J., Chamberlain, S. C. et al. (2002). Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob.Agents Chemother., 46, 2365-2372.
20. Bogner, E., Radsak, K., and Stinski, M. F. (1998). The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J. Virol., 72, 2259-2264.
21. Bogner, E. (2002). Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev. Med. Virol., 12, 115-127.
22. Borthwick, A. D. (2005). Design of translactam HCMV protease inhibitors as potent antivirals. Med. Res. Rev., 25, 427-452.
23. Borthwick, A. D., Weingarten, G., Haley, T. M. et al. (1998). Design and synthesis of monocyclic beta-lactams as mechanism-based inhibitors of human cytomegalovirus protease. Bioorg. Med. Chem. Lett., 8, 365-370.
24. Boston Consulting Group analysis based on DiMasi, J. A. et al. (1993). As quoted by The Office of Technology Assessment in Pharmaceutical Research and Development: Cost, Risks, Rewards.
25. Boulware, S. L., Bronstein, J. C., Nordby, E. C., and Weber, P. C. (2001). Identification and characterization of a benzothio-phene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection. Antivi-ral Res., 51, 111-125.
26. Bournique, B., Lambert, N., Boukaiba, R., and Martinet, M. (2001). In vitro metabolism and drug interaction poten-tial of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide). Br. J. Clin. Pharmacol., 52, 53-63.
27. Braithwaite, D. K. and Ito, J. (1993). Compilation, alignment, and phylogenetic relationships of DNA polymerases. Nucl. Acids Res., 21, 787-802.
28. Brideau, R. J., Knechtel, M. L., Huang, A. et al. (2002). Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res., 54, 19-28.
29. Brown, D. G., Visse, R., Sandhu, G. et al. (1995).Crystal structures of the thymidine kinase from herpes simplex virus type-1 in com-plex with deoxythymidine and ganciclovir. Nat. Struct. Biol., 2, 876-881.
30. Buerger, I., Reefschlaeger, J., Bender, W. et al. (2001). A novel non-nucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol., 75, 9077-9086.
31. Buerger, I., Reefschlaeger, J., Bender, W. (2001). A novel nonnucle-oside inhibitor specifically targets cytomegalovirus DNA mat-uration via the UL89 and UL56 gene products. J. Virol., 75, 9077-9086.
32. Chee, M. S., Lawrence, G. L., and Barrell, B. G. (1989). Alpha-, beta-and gammaherpesviruses encode a putative phosphotrans-ferase. J. Gen. Virol., 70(5), 1151-1160.
33. Chou, S. (2006). UL27 and UL97 resistance mutations selected after passage of clinical CMV isolates under maribavir. 31st Interna-tional Herpesvirus Workshop. 31st International Herpesvirus Workshop [Seattle, WA July 22-28; Oral Presentation 10.13].
34. Chou, S., Lurain, N. S., Thompson, K. D., Miner, R. C., and Drew, W. L. (2003). Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis., 188, 32-39.
35. Chou, S., Marousek, G. I., Senters, A. E., Davis, M. G., and Biron, K. K. (2004). Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol., 78, 7124-7130.
36. Chulay, J., Biron, K., Wang L. et al. (1999). Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv. Exp. Med Biol., 458, 129-134.
37. Ciesla, S. L., Trahan, J., Wan, W. B. et al. (2003). Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res., 59, 163-171.
38. Cirone, M., Zompetta, C., Tarasi, D., Frati, L., and Faggioni, A. (1996). Infection of human T lymphoid cells by human herpesvirus 6 is blocked by two unrelated protein tyrosine kinase inhibitors, biochanin A and herbimycin. AIDS Res. Hum. Retroviruses, 12, 1629-1634.
39. Crumpacker, C. S. and Schaffer, P. A. (2002). New anti-HSV ther-apeutics target the helicase-primase complex. Nat. Med., 8, 327-328.
40. Crute, J. J. and Lehman, I. R. (1991). Herpes simplex virus-1 helicase-primase. Physical and catalytic properties. J. Biol. Chem., 266, 4484-4488.
41. Crute, J. J., Grygon, C. A., Hargrave, K. D. et al. (2002). Herpessimplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med., 8, 386-391.
42. De Bolle, L., Andrei, G., Snoeck, R. et al. (2004). Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochem. Pharmacol., 67, 325-336.
43. De Clercq, E. (2002). Cidofovir in the therapy and short-term pro-phylaxis of poxvirus infections. Trends Pharmacol. Sci., 23, 456-458.
44. De Clercq, E. (2003a). Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyr-imidine nucleoside analogues. Med. Res. Rev., 23, 253-274.
45. De Clercq, E. (2003b). New inhibitors of human cytomegalovirus (HCMV) on the horizon. J. Antimicrob. Chemother., 51, 1079-1083.
46. De Miranda, P. and Burnette, T. C. (1994). Metabolic fate and phar-macokinetics of the acyclovir prodrug valaciclovir in cynomol-gus monkeys. Drug Metab. Dispos., 22, 55-59.
47. De Miranda, P. and Good, S. S. (1992). Species differences in the metabolism and disposition of antiviral analogues. Antiviral Chem. Chemo., 3, 1-8.
48. Diana, G. D., Oglesby, R. C., Akullian, V. et al. (1987). Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: Inhibitors of picornavirus uncoating. J. Med. Chem., 30, 383-388.
49. Dittmer, A., Drach, J. C., Townsend, L., Fischer, A., and Bogner, E. (2005). Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides. J. Virol., 79, 14660-14667.
50. Docherty, J. J., Fu, M. M., Stiffier, B. S., Limperos, R. J., Pokabla, C. M., and DeLucia, A. L. (1999). Resveratrol inhibition of her-pes simplex virus replication. Antiviral Res., 43, 145-155.
51. Dunkle, L. M. (1996). Lobucavir: A promising broad-spectrum antiviral agent. Eleventh International Conference on AIDS, Vancouver, abstract Th.B.943.
52. Elion, G. B., Furman, P. A., Fyfe, J. A., de Miranda, P., Beauchamp, L., and Schaeffer, H. J. (1977). Selectivity of action of an antiher-petic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl Acad. Sci. USA, 74, 5716-5720.
53. Erickson, J., Neidhart, D. J., VanDrie, J. et al. (1990). Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor com-plexed to HIV-1 protease. Science, 249, 527-533.
54. Evers, D. L., Komazin, G., Ptak, R. G. et al. (2004). Inhibition of human cytomegalovirus replication by benzimidazole nucle-osides involves three distinct mechanisms. Antimicrob. Agents Chemother., 48, 3918-3927.
55. Franklin, M. C., Wang, J., and Steitz, T. A. (2001). Structure of the replicating complex of a pol alpha family DNA polymerase. Cell, 105, 657-667.
56. Gershburg, E. and Pagano, J. S. (2002). Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity fac-tor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. J. Virol., 76, 998-1003.
57. Gibson, W., Welch, A. R., and Hall, W. R. T. (1994). Assembling a herpesvirus serine maturational proteinase and a new molec-ular target for antivirals. Perspect Drug Discov Design, 2, 413-416.
58. Good, S. S., Owens, B. S., Townsend, L. B., and Drach, J. C.(1994). The disposition in rats and monkeys of 2-bromo-5,6,-dicholoro-1-(beta-ribofuranosyl)benzimididazole (BDCRB) and its 2,5,6-trichloro congener (TCRB). Antivir. Res., 23, 103.
59. Hall, M. C. and Matson, S. W. (1999). Helicase motifs: The engine that powers DNA unwinding. Mol. Microbiol., 34, 867-877.
60. Hamilton, H. W., Nishiguchi, G., Hagen, S. E. et al. (2002). Novel ben-zthiodiazepinones as antiherpetic agents: SAR improvement of therapeutic index by alterations of the seven-membered ring. Bioorg. Med Chem. Lett., 12, 2981-2983.
61. Hasegawa, Y., Nishiyama, Y., Imaizumi, K. et al. (2000). Avoidance of bone marrow suppression using A-5021 as a nucleoside analog for retrovirus-mediated herpes simplex virus type I thymidine kinase gene therapy. Cancer Gene Ther., 7, 557-562.
62. He, Z., He, Y. S., Kim, Y. et al. (1997). The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J. Virol., 71, 405-411.
63. Hemmi, H., Kaisho, T., Takeuchi, O. et al. (2002). Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol., 3, 196-200.
64. Henry, S. P., Miner, R. C., Drew, W. L. et al. (2001). Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication. Invest.Ophthalmol. Vis.Sci., 42, 2646-2651.
65. Herget, T., Freitag, M., Morbitzer, M., Kupfer, R., Stamminger, T., and Marschall, M. (2004). Novel chemical class of pUL97 pro-tein kinase-specific inhibitors with strong anticytomegaloviral activity. Antimicrob. Agents Chemother., 48, 4154-4162.
66. Holwerda, B. C. (1997). Herpesvirus proteases: Targets for novel antiviral drugs. Antiviral Res., 35, 1-21.
67. Hoog, S. S., Smith, W. W., Qiu, X. et al. (1997). Active site cavity of herpesvirus proteases revealed by the crystal structure of her-pes simplex virus protease/inhibitor complex. Biochemistry, 56, 14023-14029.
68. Hu, H. and Cohen, J. I. (2005). Varicella-zoster virus open read-ing frame 47 (ORF47) protein is critical for virus replication in dendritic cells and for spread to other cells. Virology, 337, 304-311.
69. Huggins, J. W., Baker, R. O., Beadle, J. R., and Hostetler, K. Y. (2002). Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox. Antivir. Res., 53, A66, 104.
70. Iwayama. S., Ono. N., Ohmura, Y. et al. (1998). Antiherpesvirus activities of (1? S,2? R)-9-[[1?,2?-bis(hydroxymethyl)cycloprop-1?-yl]methyl]guanine (A-5021) in cell culture. Antimicrob. Agents Chemother., 42, 1666-1670.
71. Iwayama, S., Ohmura, Y., Suzuki, K. et al. (1999). Eval-uation of anti-herpesvirus activity of (1? S,2? R)-9-[[1?,2?-bis(hydroxymethyl)cycloprop-1?-yl]methyl]-guanine (A-5021) in mice. Antiviral Res., 42, 139-148.
72. Jacobson, J. G., Renau, T. E., Nassiri, M. R. et al. (1999). Non-nucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus. Antimicrob. Agents Chemother., 43, 1888-1894.
73. Kato, A., Yamamoto, M., Ohno, T. et al. (2006). Herpes simplex virus 1-encoded protein kinase UL13 phosphorylates viral Us3 pro-tein kinase and regulates nuclear localization of viral envelop-ment factors UL34 and UL31. J. Virol., 80, 1476-1486.
74. Kawaguchi, Y. and Kato, K. (2003). Protein kinases conserved in her-pesviruses potentially share a function mimicking the cellular protein kinase cdc2. Rev. Med. Virol., 13, 331-340.
75. Kern, E. R. (2003). In vitro activity of potential anti-proxvirus agents. Antiviral Res., 57, 35-40.
76. Kern, E. R., Collins, D. J., Wan, W. B., Beadle, J. R., Hostetler, K. Y., and Quenelle, D. C. (2004a). Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob. Agents Chemother., 48, 3516-3522.
77. Kleymann, G. (2003a). Novel agents and strategies to treat herpes simplex virus infections. Expert. Opin. Investig. Drugs, 12, 165-183.
78. Kleymann, G. (2003b). Helicase-primase inhibitors. Drugs of the Future, 28, 257-265.
79. Kleymann, G., Fischer, R., Betz, U. A. et al. (2002). New helicase-primase inhibitors as drug candidates for the treatment of her-pes simplex disease. Nat. Med., 8, 392-398.
80. Knechtel, M. L., Huang, A., Vaillancourt, V. A., and Brideau, R. J. (2002). Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU-183792, a 4-oxo-dihydroquinoline. J. Med. Virol., 68, 234-236.
81. Komatsu, T., Ballestras, M. E., Barbera, A. J., Kelly-Clarke, B., and Kaye, K. M. (2004). KSHV LA NA-1 binds DNA as an oligomer and residues N-terminal to the oligomerization domain are essential for DNA replication and episome persistence. Virol-ogy, 319, 225-236.
82. Koszalka, G. W., Johnson, N. W., Good, S. S. (2002). Preclinicat and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother, 46, 2373-2380.
83. Komazin, G., Ptak, R. G., Emmer, B. T., Townsend, L. B, and Drach, J. C. (2003). Resistance of human cytomegalovirus to the ben-zimidazole L-ribonucleoside maribavir maps to UL27. J Virol., 77, 11499-11506.
84. Komazin, G., Townsend, L. B., and Drach, J. C. (2004). Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides. J. Virol., 78, 710-715.
85. Krosky, P. M., Baek, M. C., Jahng, W. J. et al. (2003b). The human cytomegalovirus UL44 protein is a substrate for the UL97 pro-tein kinase. J. Virol., 77, 7720-7727.
86. Krosky, P. M., Baek, M. C., and Coen, D. M. (2003a). The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol., 77, 905-914.
87. Krosky, P. M., Underwood, M. R., Turk, S.R. et al. (1998). Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol., 72, 4721-4728.
88. LaBranche, C. C., Galasso, G., Moore, J. P., Bolognesi, D. P., Hirsch, M. S., and Hammer, S. M. (2001). HIV fusion and its inhibition. Antiviral Res., 50, 95-115.
89. Lalezari, J. P. (1997). New treatment options for CMV retinitis in AIDS. Adv. Nurse Pract., 5, 45-9.
90. Lalezari, J. P., Drew, W. L., Glutzer, E. et al. (1995). (S)-1[3-hydroxy-2-(phosphonylmethoxy)propyl] cytosine (cidofovir): Results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis., 171, 788-796.
91. Lalezari, J. P., Aberg, J. A., Wang, L. H. et al. (2002). Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymp-tomatic HCMV shedding. Antimicrob. Agents Chemother., 46, 2969-2976.
92. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001). Experimental and computational approaches to estimate sol-ubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 46, 3-26
93. Littler, E., Stuart, A. D., and Chee, M. S. (1992). Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganci-clovir. Nature, 358, 160-162.
94. Liuzzi, M., Kibler, P., Bousquet, C. et al. (2004). Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase. Antiviral Res., 64, 161-170.
95. Loregian, A., and Coen, D. M.(2006). Selectiveanti-cytomegalovirus compounds discoverd by screening for inhibitors of subunit interactions of the viral polymerase, Chem. Biol., 13, 191-200.
96. Lorenzi, P. L., Landowski, C. P., Brancale, A. et al. (2006). N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole. Drug Metab. Dispos., 34, 1070-1077.
97. Lorenzi, P. L., Landowski, C. P., Song, X. et al. (2005). Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J. Pharmacol. Exp. Ther., 314, 883-890.
98. Lowden, C. T. and Bastow, K. F. (2003). Cell culture replication of her-pes simplex virus and, or human cytomegalovirus is inhibited by 3,7-dialkoxylated, 1-hydroxyacridone derivatives. Antiviral Res., 59, 143-154.
99. Lowe, D. M., Alderton, W. K., Ellis M. R. et al. (1995). Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob. Agents Chemother., 39, 1802-1808.
100. Lu, H. and Thomas, S. (2004). Maribavir (ViroPharma). Curr. Opin. Investig. Drugs, 5, 898-906.
101. Lurain, N. S., Weinberg, A., Crumpacker, C. S., and Chou S. (2001). Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob. Agents Chemother., 45, 2775-2780.
102. Ma, J. D., Nafziger, A. N., Villano, S. A., and J. S., Jr. (2006). Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob. Agents Chemother., 50, 1130-1135
103. Marschall, M., Stein-Gerlach, M., Freitage, M., Kupfer, R., van Den, BM., and Stamminger, T. (2001). Inhibitors of human cytomegalovirus replication drastically reduce the activ-ity of the viral protein kinase pUL97. J.Gen. Virol., 82, 1439-1450.
104. Marschall, M., Freitag, M., Suchy, P. et al. (2003). The protein kinase pUL97 ofhumancytomegalovirusinteractswithandphospho-rylates the DNA polymerase processivity factor pUL44. Virol-ogy, 311, 60-71.
105. Marschall, M., Marzi, A., aus dem, S. P., et al., (2005). Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J. Biol. Chem., 280, 33357-33367.
106. Matthews, J. T., Terry, B. J., and Field, A. K. (1993). The structure and function of the HSV DNA replication proteins: Defining novel antiviral targets. Antiviral Res., 20, 89-114.
107. McGuigan, C., Jukes, A., Blewett, S. et al. (2003). Halophenyl fura-nopyrimidines as potent and selective anti-VZV agents. Antivir. Chem. Chemother., 14, 165-170.
108. McSharry, J. J., McDonough, A., Olson, B. et al. (2001a). Susceptibili-ties of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir. Antimicrob. Agents Chemother., 45, 2925-2927.
109. McSharry, J. J., McDonough, A., Olson, B., Talarico, C., Davis, M., and Biron, K. K. (2001b). Inhibition of ganciclovir-susceptible and-resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin. Diagn. Lab. Immunol., 8, 1279-1281.
110. McVoy, M. A. and Nixon, D. E. (2005). Impact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation. J. Virol., 79, 11115-11127.
111. Mettenleiter, T. C. (2002). Herpesvirus assembly and egress. J Virol., 76, 1537-1547.
112. Michel, D., Pavic, I., Zimmermann, A. et al. (1996). The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J. Virol., 70, 6340-6346.
113. Miller, R. L., Tomai, M. A., Harrison, C. J., and Bernstein, D. I. (2002). Immunomodulation as a treatment strategy for genital herpes: Review of the evidence. Int. Immunopharmacol., 2, 443-451.
114. Moffat, J. F., Zerboni, L., Sommer, M. H. et al. (1998). The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc. Natl Acad. Sci. USA, 95, 11969-11974.
115. Nagelschmitz, J., Moeller, J. G., Stass, H. H., Wadel, C., and Kuhlmann, J. (1999). Safety, tolerability, and pharmacokinet-ics of single oral doses of BAY 38-4766-a novel nonnucle-osidic inhibitor of human cytomegalovirus (HCMV) replica-tion-in healthy male subjects. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrob Agents and Chemother, San Francisco, CA, Abstract 945, 322.
116. Naesens, L., Stephens, C. E., Andrei, G. et al. (2006). Antiviral proper-ties of new arylsulfone derivatives with activity against human betaherpesviruses. Antiviral Res., in press.
117. Newcomb, W. W. and Brown, J. C. (2002). Inhibition of herpes simplex virus replication by WAY-150138: Assembly of capsids depleted of the portal and terminase proteins involved in DNA encapsidation. J Virol., 76, 10084-10088.
118. Newcomb, W. W., Juhas, R. M., Thomsen, D. R. et al. (2001). The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. J. Virol., 75, 10923-10932.
119. Newcomb, W. W., Juhas, R. M., Thomsen, D. R. et al. (2001). The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. J. Virol., 75, 10923-10932.
120. Newcomb, W. W., Thomsen, D. R., Homa, F. L., and Brown, J. C. (2003). Assembly of the herpes simplex virus capsid: Identification of soluble scaffold-portal complexes and their role in formation of portal-containing capsids. J. Virol., 77, 9862-9871.
121. Neyts, J. and De Clercq, E. (2001). The anti-herpesvirus activity of (1? S,2? R)-9-[[1?,2?-bis(hydroxymethyl)-cycloprop-1?-yl]methyl]guanine is markedly potentiated by the immuno-suppressive agent mycophenolate mofetil. Antiviral Res., 49, 121-127.
122. Neyts, J., Naesens, L., Ying, C., De Bolle, L., and De Clercq, E. (2001). Anti-herpesvirus activity of (1? S,2? R)-9-[[1?, 2?-bis(hydroxymethyl)-cycloprop-1?-yl]methyl] x guanine (A-5021) in vitro and in vivo. Antiviral Res., 49, 115-120.
123. Neyts, J., Leyssen, P., Verbeken, E., and De Clercq, E. (2004). Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother., 48, 2267-2273.
124. Ng, T. I., Shi, Y., Huffaker, H. J. et al. (2001). Selection and character-ization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine. Antimicrob. Agents Chemother., 45, 1629-1636.
125. Oien, N. L., Brideau, R. J., Hopkins, T. A. et al. (2002). Broad-spectrum antiherpes activities of 4-hydroxyquinoline carbox-amides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother., 46, 724-730.
126. Okano, M.(2003). Theevolvingtherapeuticapproachesfor Epstein-Barr virus infection in immunocompetent and immunocom-promised individuals. Curr. Drug Targets. Immune. Endocr. Metabol. Disord., 3, 137-142.
127. Ono, N., Iwayama, S., Suzuki, K. et al. (1998). Mode of action of (1? S,2? R)-9-[[1?,2?-bis(hydroxymethyl) cycloprop-1?-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus. Antimicrob. Agents Chemother., 42, 2095-2102.
128. Painter, G. R. and Hostetler, K.Y. (2004). Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol., 22, 423-427.
129. Prichard, M. N., Britt, W. J., Daily, S. L., Hartline, C. B., and Kern, E. R. (2005). Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J. Virol., 79, 15494-15502.
130. Prichard, M. N., Gao, N., Jairath, S. et al. (1999). A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol., 73, 5663-5670.
131. Przech, A. J., Yu, D., and Weller, S. K. (2003). Point mutations in exon I of the herpes simplex virus putative terminase subunit, UL15, indicate that the most conserved residues are essential for cleavage and packaging. J. Virol., 77, 9613-9621.
132. Qiu, X. Y. and Abdelmeguid, S. S. (1999). Human herpes proteases In Dunn, B. M., ed. Proteases of Infectious Agents. San Diego: Academic Press, 93-115.
133. Razonable, R. R., Brown, R. A., Humar, A., Covington, E., Alecock, E., and Paya, C. V. (2005). Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J. Infect. Dis., 192, 1331-1339.
134. Rechtsteiner, G., Warger, T., Osterloh, P., Schild, H., and Radsak, M. P. (2005). Cutting edge: Priming of CTL by transcutaneous pep-tide immunization with imiquimod. J. Immunol. 174, 2476-2480.
135. Reefschlaeger, J., Bender, W., Hallenberger, S. et al. (2001). Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): In vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother., 48, 757-767.
136. Roizman, B., Whitley, R. J., and Lopez, C., eds. (1993). The Human Herpesvireses. New York, NY: Raven Press.
137. Safrin, S., Cherrington, J., and Jaffe, H. S. (1997). Clinical uses of cidofovir. Rev. Med. Virol., 7, 145-156.
138. Sakuma, T., Saijo, M., Suzutani, T. et al. (1991). Antiviral activity of oxetanocins against varicella-zoster virus. Antimicrob. Agents Chemother., 35, 1512-1514.
139. Schang, L. M. (2002). Cyclin-dependent kinases as cellular tar-gets for antiviral drugs. J. Antimicrob. Chemother., 50, 779-792.
140. Schang, L. M., Bantly, A., Knockaert, M. et al. (2002). Pharmaco-logical cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellu-lar, not viral, proteins. J. Virol., 76, 7874-7882.
141. Scheffczik, H., Savva, C. G., Holzenburg, A., Kolesnikova, L., and Bogner, E. (2002). The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucl. Acids Res., 30, 1695-1703.
142. Scolnick, E. M., Richards, F. M., Eisenberg, D. S., and Kim, P. S., eds. (2001). Drug Discovery and Design (Advances in Protein Chemistry) 51, Academic Press.
143. Sekiyama, T., Hatsuya, S., Tanaka, Y. et al. (1998). Synthesis and antiviral activity of novel acyclic nucleosides: Discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses. J. Med. Chem., 41, 1284-1298.
144. Shin, Y. K., Cai, G. Y., Weinberg, A., Leary, J. J., and Levin, M. J. (2001). Frequencyofacyclovir-resistantherpessimplexvirusin clinical specimens and laboratory isolates. J. Clin. Microbiol., 39, 913-917.
145. Shugar, D. (1999). Viral and host-cell protein kinases: Enticing antiviral targets and relevance of nucleoside, and viral thymi-dine, kinases. Pharmacol. Ther., 82, 315-335.
146. Sienaert, R., Andrei, G., Snoeck, R., De Clercq, E., McGuigan, C., and Balzarini, J. (2004). Inactivity of the bicyclic pyrimidine nucle-oside analogues against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymi-dine kinase. Biochem. Biophys. Res. Commun., 315, 877-883.
147. Sienaert, R., Naesens, L., Brancale, A., De Clercq, E., McGuigan, C., and Balzarini, J. (2002). Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol. Pharmacol., 61, 249-254.
148. Simpson-Holley, M., Baines, J., Roller, R., and Knipe, D. M. (2004). Herpes simplex virus 1 U(L)31 and U(L)34 gene products pro-mote the late maturation of viral replication compartments to the nuclear periphery. J. Virol., 78, 5591-5600.
149. Slater, M. J., Cockerill, S., Baxter, R. et al. (1999). Indolocarbazoles: Potent, selective inhibitors of human cytomegalovirus repli-cation. Bioorg. Med. Chem., 7, 1067-1074.
150. Smith, R. F. and Smith, T. F. (1989). Identification of new protein kinase-related genes in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus. J. Virol., 63, 450-455.
151. Snoeck, R., Andrei, G., Bodaghi, B. et al. (2002). 2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Res., 55, 413-424.
152. Soike, K. F., Bohm, R., Huang, J. L., and, Oberg, B. (1993). Efficacy of (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virus. Antimicrob. Agents Chemother., 37, 1370-1372.
153. Spector, F. C., Liang, L., Giordano, H., Sivaraja, M., and Peterson, M. G. (1998). Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J. Virol., 72, 6979-6987.
154. Spence, R. A., Kati, W. M., Anderson, K. S., and Johnson, K. A. (1995). Mechanism of inhibition of HIV-1 reverse transcrip-tase by nonnucleoside inhibitors. Science, 267, 988-993.
155. Stamminger, T., Gstaiger, M., Weinzierl, K., Lorz, K., Winkler, M., and Schaffner, W. (2002). Open reading frame UL26 of human cytomegalovirus encodes a novel tegument protein that con-tains a strong transcriptional activation domain. J. Virol., 76, 4836-4847.
156. Sullivan, V., Talarico, C. L., Stanat, S. C., Davis, M., Coen, D. M., and Biron, K. K. (1992). A protein kinase homologue controls phos-phorylation of ganciclovir in human cytomegalovirus-infected cells. Nature, 359, 85.
157. Supuran, C. T., Casini, A., and Scozzafava, A. (2003). Protease inhibitors of the sulfonamide type: Anticancer, antiinfiamma-tory, and antiviral agents. Med. Res. Rev., 23, 535-558.
158. Talarico, C. L., Burnette, T. C., Miller, W. H. et al. (1999). Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob. Agents Chemother., 43, 1941-1946.
159. Tenney, D. J., Yamanaka, G., Voss, S. M. et al. (1997). Lobu-cavir is phosphorylated in human cytomegalovirus-infected and-uninfected cells and inhibits the viral DNA polymerase. Antimicrob. Agents Chemother., 41, 2680-2685.
160. Thoma, C., Borst, E., Messerle, M., Rieger, M., Hwang, J. S. and Bogner, E. (2006). Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus. Biochemistry, 45, 8855-8863.
161. Thomsen, D. R., Oien, N. L., Hopkins, T. A. et al. (2003). Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resis-tance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. J. Virol., 77, 1868-1876.
162. Thomsen, L. L., Topley, P., Daly, M. G., Brett, S. J., and Tite, J. P. (2004). Imiquimod and resiquimod in a mouse model: Adju-vants for DNA vaccination by particle-mediated immunother-apeutic delivery. Vaccine, 22, 1799-1809.
163. Townsend, L. B. and Revankar, G. R. (1970). Benzimidazole nucle-osides, nucleotides, and related derivatives. Chem. Rev., 70, 389-438.
164. Townsend, L. B., Devivar, R. V., Turk, S. R., Nassiri, M. R., and Drach, J. C. (1995). Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-l-(beta-D-ribofuranosyl)benzimidazoles. J. Med. Chem., 38, 4098-4105.
165. Townsend, L. B., Gudmundsson, K. S., Daluge, S. M. et al. (1999). Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB. Nucle-osides Nucleotides, 18, 509-519.
166. Tsai, C. J., Lin, S. L., Wolfson, H. J., and Nussinov, R. (1997). Stud-ies of protein-protein interfaces: A statistical analysis of the hydrophobic effect. Protein Sci., 6, 53-64.
167. Underwood, M. R., Harvey, R. J., Stanat, S. C. et al. (1998). Inhibi-tion of human cytomegalovirus DNA maturation by a benz-imidazole ribonucleoside is mediated through the UL89 gene product. J. Virol., 72, 717-725.
168. Vaillancourt, V. A., Cudahy, M. M., Staley, S. A. et al. (2000). Naph-thalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase. Bioorg. Med. Chem. Lett., 10, 2079-2081.
169. Van Zeijl, M., Fairhurst, J., Baum, E. Z., Sun, L., and Jones, T. R.(1997). The human cytomegalovirus UL97 protein is phosphory lated and a component of virions. Virology, 231, 72-80.
170. van Zeijl, M., Fairhurst, J., Jones, T. R. et al. (2000). Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: Resistance maps to the UL6 gene. J. Virol., 74, 9054-9061.
171. Visalli, R. J. and van Zeijl, M. (2003). DNA encapsidation as a tar-get for antiherpesvirus drug therapy. Antiviral Res., 59, 73-87.
172. Visalli, R. J., Fairhurst, J., Srinivas, S. et al. (2003). Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J. Virol., 77, 2349-2358.
173. Wang, L. H., Peck, R. W., Yin, Y., Allanson, J., Wiggs, R., and Wire, M. W. (2003). Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subject. Antimicrob. Agents Chemother., 47, 1334-1342.
174. Wan, W. B., Beadle, J. R., Hartline, C. et al. (2005). Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cido-fovir against human and murine cytomegalovirus replication in vitro. Antimicrob. Agents. Chemother., 49, 656-662.
175. Wathen, M. W. (2002). Non-nucleoside inhibitors of herpesviruses. Rev. Med. Virol., 12, 167-178.
176. Waxman, L. and Darke, P. L. (2000). The herpesvirus proteases as targets for antiviral chemotherapy. Antivir. Chem. Chemother., 11, 1-22.
177. Wang, Y., Abel, K., Lantz, K., Krieg, A. M., McChesney, M. B., and Miller, C. J. (2005). The Toll-like receptor 7 (TLR7) ago-nist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vagi-nal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J. Virol., 79, 14355-14370.
178. Weber, O., Bender, W., Eckenberg, P. et al. (2001). Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res., 49, 179-189.
179. White, C. A., Stow, N. D., Patel, A. H., Hughes, M., and Preston, V. G. (2003). Herpes simplex virus type 1 portal protein UL6 interacts with the putative terminase subunits UL15 and UL28. J Virol., 77, 6351-6358.
180. Williams, S. L., Hartline, C. B., Kushner, N. L. et al. (2003). In vitro activities of benzimidazole D-and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother., 47, 2186-2192.
181. Williams-Aziz, S. L., Hartline, C. B., Harden, E. A. et al. (2005). Com-parative activities of lipid esters of cidofovir and cyclic cido-fovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother., 49, 3724-3733.
182. Wolf, D. G., Courcelle, C. T., Prichard, M. N., and Mocarski, E. S. (2001). Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsi-dation. Proc. Natl Acad. Sci. USA, 98, 1895-1900.
183. Wolf, D. G., Courcelle, C. T., Prichard, M. N., and Mocarski, E. S. (2001). Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsi-dation. Proc. Natl Acad. Sci. U.S.A, 98, 1895-1900.
184. Zacny, V. L., Gershburg, E., Davis, M. G., Biron, K. K., and Pagano, J. S. (1999). Inhibition of Epstein-Barr virus replica-tion by a benzimidazole L-riboside: Novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J Virol., 73, 7271-7277.
185. Zimmermann, A., Wilts, H., Lenhardt, M., Hahn, M., and Mertens, T. (2000). Fifteenth International Conference on Antiviral Res. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Res., 48, 49-60.